Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models-Reference-Cited by-同舟云学术

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models

Published:2017-07-06 Issue:5 Volume:117 Page:628-638
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Belgiovine Cristina,Bello Ezia,Liguori Manuela,Craparotta Ilaria,Mannarino Laura,Paracchini Lara,Beltrame Luca,Marchini Sergio,Galmarini Carlos M,Mantovani Alberto,Frapolli Roberta,Allavena Paola,D'Incalci Maurizio

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2017205.pdf

Reference44 articles.

1. Allavena P, Mantovani A (2012) Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 167 (2): 195–205.

2. Belgiovine C, D’Incalci M, Allavena P, Frapolli R (2016) Tumor-associated macrophages and anti-tumor therapies: complex links. Cell Mol Life Sci 73 (13): 2411–2424.

3. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol) 57 (1): 289–300.

4. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT (2013) Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 19 (12): 3165–3175.

5. Breitling R, Armengaud P, Amtmann A, Herzyk P (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573 (1–3): 83–92.

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small Cell Lung Cancer—An Update on Chemotherapy Resistance;Current Treatment Options in Oncology;2024-07-27

2. An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023);Journal of Medicinal Chemistry;2024-07-12

3. The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer;Cancer Treatment Reviews;2024-07

4. Harnessing the innate immune system by revolutionizing macrophage-mediated cancer immunotherapy;Journal of Biosciences;2024-06-04

5. Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors;Critical Reviews in Oncology/Hematology;2024-06